Markers of bacterial translocation as a possible indicator of subclinical inflammation in pediatric inflammatory bowel diseases patients
Year: 2025
Type: article
Study design: Observational Study
Abstract: Introduction: Recently there has been significant progress in research on the pathogenesis of inflammatory bowel diseases (IBD).Aim: Our study aimed to assess selected markers of bacterial translocation in children with IBD in relationship to disease activity.Material and methods: Lipopolysaccharides (LPS) -markers of bacterial translocation -and proinflammatory cytokines -interleukin (IL)-8, IL-12 and tumor necrosis factor (TNF) α -were assessed in the serum of 27 pediatric IBD patients at the outbreak of the illness and then 1 and 3 months after the introduction of the treatment.The analyzed markers were taken once in 6 healthy children in the control group.Results: Serum TNF-α and LPS concentrations were significantly higher in IBD patients than in the control group (1.74 vs. 0.83 ng/ml and 21.83 vs. 10.26 pg/ml, p < 0.05).In the study group, clinical and laboratory activity mediators significantly decreased during 3 months of the treatment.All proinflammatory cytokines decreased, but significant down-regulation was observed only in relation to IL-12 (129.21 vs. 82.98pg/ml, p < 0.05) in CD and IL-8 (32.72 vs. 20.97pg/ml, p < 0.05) in UC patients.TNF-α levels decreased but did not reach values as in healthy children, while LPS levels increased in both groups.Conclusions: IL-12 in CD and IL-8 in UC could be non-invasive markers of reduced inflammation during IBD in children.Improvements in clinical status and reductions in systemic inflammatory markers do not necessarily mean complete cessation of the inflammatory cascade.The elevated TNF-α and LPS levels found in patients in early remission may be a marker of subclinical inflammation.
Source: Gastroenterology Review
Institutions: Jagiellonian University, Uniwersytecki Szpital Dziecięcy
Language: English
Topic: Inflammatory Bowel Disease
Subfield: Genetics
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $103
OpenAlex ID: W4411241156